David McNinch is a seasoned biopharma senior leader who has been in the industry for 25 years and worked for large pharma, large biotech, and a number of emerging companies. David has extensive experience developing new product commercialization strategies as well as launching and growing biotech brands across multiple therapeutic areas. For the past 15 years, David has focused on orphan and rare diseases and building companies to commercialize them. Most recently, he has been engaged in the gene therapy and ‘curative therapy’ landscape and the implications on corporate development, commercialization, and reimbursement. David has a strong commitment to patient advocacy. He is a former board member for National Huntington’s Disease Society and current Vice Chair for Pulmonary Fibrosis Foundation.